Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1641 1644
This examiner grants 50% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18249708 | INJECTABLE HYDROGELS FOR ADOPTIVE CELL THERAPY | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 19238328 | ENGINEERED BISPECIFIC MOLECULES AND METHODS OF USE | Final Rejection | Cantai Therapeutics Inc. |
| 18013864 | METHODS TO GLYCOENGINEER PROTEINS | Final Rejection | THE JOHNS HOPKINS UNIVERSITY |
| 17997171 | TREATMENT AND PREVENTION OF ALLOREACTIVITY USING VIRUS-SPECIFIC IMMUNE CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTORS | Non-Final OA | Baylor College of Medicine |
| 18456317 | OPTIMIZED Fc VARIANTS | Non-Final OA | Xencor, Inc. |
| 17880358 | IMMUNOGLOBULIN FC CONJUGATE WHICH MAINTAINS BINDING AFFINITY OF IMMUNOGLOBULIN FC FRAGMENT TO FCRN | Final Rejection | HANMI PHARM. CO., LTD. |
| 17349482 | POTENCY ASSAYS FOR ANTIBODY DRUG SUBSTANCE BINDING TO AN FC RECEPTOR | Final Rejection | GENMAB A/S |
| 18100885 | HUMANIZED ANTI-COMPLEMENT FACTOR C1Q ANTIBODIES AND USES THEREOF | Non-Final OA | Annexon, Inc. |
| 18016436 | SERUM STABLE BINDING PROTEINS FOR HUMAN HER2 FOR THERANOSTIC APPLICATIONS | Non-Final OA | Navigo Proteins GmbH |
| 18303303 | USE OF AN ANTI-CD19 ANTIBODY TO TREAT AUTOIMMUNE DISEASE | Non-Final OA | Viela Bio, Inc. |
| 18245959 | COMPOUND FOR THE SEQUESTRATION OF UNDESIRABLE ANTIBODIES IN A PATIENT | Non-Final OA | ABLEVIA BIOTECH GMBH |
| 18162308 | FUSION PROTEINS OF HUMAN PROTEIN FRAGMENTS TO CREATE ORDERLY MULTIMERIZED IMMUNOGLOBULIN FC COMPOSITIONS WITH ENHANCED FC RECEPTOR BINDING | Non-Final OA | Gliknik Inc. |
| 18061755 | COMPOSITIONS FOR INCREASING HALF-LIFE OF A THERAPEUTIC AGENT IN CANINES AND METHODS OF USE | Non-Final OA | Invetx, Inc. |
| 17800630 | MODIFIED FC REGIONS | Non-Final OA | adivo GmbH |
| 17745667 | POLYPEPTIDE VARIANTS AND USES THEREOF | Final Rejection | GENMAB B.V. |
| 17684238 | ANTI-DEATH RECEPTOR ANTIBODIES AND METHODS OF USE THEREOF | Final Rejection | GENMAB B.V. |
| 17622333 | ANTIBODIES FOR BINDING PSMA WITH REDUCED AFFINITY FOR THE NEONATAL FC RECEPTOR | Final Rejection | Telix Pharmaceuticals (Innovations) Pty Ltd |
| 16772244 | VARIANTS WITH FC FRAGMENT HAVING AN INCREASED AFFINITY FOR FCRN AND AN INCREASED AFFINITY FOR AT LEAST ONE RECEPTOR OF THE FC FRAGMENT | Final Rejection | LABORATOIRE FRANÇAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES |
| 16317987 | BISPECIFIC PROTEINS AND METHODS FOR PREPARING SAME | Final Rejection | Ibentrus, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy